{"id":"W2947105388","doi":"10.1200/jco.2019.37.15_suppl.1013","title":"Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Internal medicine; Triple-negative breast cancer; Taxane; Clinical endpoint; Cohort; Oncology; Breast cancer; Tolerability; Phases of clinical research; Paclitaxel; Cancer; Gastroenterology; Adverse effect; Toxicity; Clinical trial; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001930156,0.0005796464,0.003494726,0.0002999234,0.0002433624,0.00002934771,0.0003242347,0.0003065386,0.001046607],"category_scores_gemma":[0.002178338,0.0003094624,0.0007444128,0.0004594003,0.0004272122,0.0003226862,0.0001064066,0.0008655736,0.00005557182],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001426275,"about_ca_system_score_gemma":0.006238477,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002617328,"about_ca_topic_score_gemma":0.0007944539,"domain_scores_codex":[0.993668,0.0006804912,0.003036993,0.0007250531,0.001044786,0.0008446569],"domain_scores_gemma":[0.9891112,0.004429718,0.002536779,0.0004947647,0.00241867,0.001008866],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4788156,0.100278,0.0575427,0.000244349,0.008356477,0.001120678,0.001131297,0.0001357321,0.00003720195,0.00002300475,0.002760191,0.3495548],"study_design_scores_gemma":[0.3497278,0.5713697,0.02193212,0.0004142819,0.003044475,0.0002430514,0.001242075,0.0002073282,0.0001026919,0.0001552222,0.05122721,0.0003340744],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9806274,0.0006396491,0.00009080395,0.009068756,0.001167964,0.007245701,0.0006706668,0.00002796453,0.0004610712],"genre_scores_gemma":[0.9832806,0.002414784,0.002629003,0.001206876,0.0006178991,0.0005869246,0.00006556133,0.00009474938,0.009103624],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4710917,"threshold_uncertainty_score":0.9999357,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1101164755050476,"score_gpt":0.505768883853412,"score_spread":0.3956524083483645,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}